Nanobac Pharmaceuticals, Incorporated (NNBP)
USD 0.0
(0.0%)
USD 0.0
(0.0%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2007 | 3102.00 USD | -97.86% |
| 2006 | 145.28 Thousand USD | -66.0% |
| 2005 | 427.35 Thousand USD | 65.71% |
| 2004 | 257.89 Thousand USD | 72.28% |
| 2003 | 149.69 Thousand USD | 1967.87% |
| 2002 | 7239.00 USD | 0.0% |
| 1999 | 2.43 Million USD | -28.24% |
| 1998 | 3.38 Million USD | -26.51% |
| 1997 | 4.61 Million USD | 14.51% |
| 1996 | 4.02 Million USD | 49.13% |
| 1995 | 2.7 Million USD | 28.57% |
| 1994 | 2.1 Million USD | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2007 Q1 | 752.00 USD | -54.15% |
| 2007 FY | 3102.00 USD | -97.86% |
| 2007 Q4 | 678.00 USD | -40.63% |
| 2007 Q3 | 1142.00 USD | 115.47% |
| 2007 Q2 | 530.00 USD | -29.52% |
| 2006 FY | 145.28 Thousand USD | -66.0% |
| 2006 Q1 | 116.09 Thousand USD | -8.22% |
| 2006 Q3 | 12.6 Thousand USD | -15.62% |
| 2006 Q4 | 1640.00 USD | -86.99% |
| 2006 Q2 | 14.94 Thousand USD | -87.13% |
| 2005 Q4 | 126.49 Thousand USD | 51.84% |
| 2005 Q3 | 83.3 Thousand USD | -23.94% |
| 2005 Q2 | 109.52 Thousand USD | 1.39% |
| 2005 FY | 427.35 Thousand USD | 65.71% |
| 2005 Q1 | 108.02 Thousand USD | -5.72% |
| 2004 Q1 | 25.19 Thousand USD | -77.26% |
| 2004 FY | 257.89 Thousand USD | 72.28% |
| 2004 Q4 | 114.58 Thousand USD | 50.7% |
| 2004 Q3 | 76.03 Thousand USD | 26.84% |
| 2004 Q2 | 59.94 Thousand USD | 137.93% |
| 2003 Q4 | 110.77 Thousand USD | 187.71% |
| 2003 FY | 149.69 Thousand USD | 1967.87% |
| 2003 Q3 | 38.5 Thousand USD | 1169.05% |
| 2003 Q1 | -10.29 Thousand USD | 0.0% |
| 2003 Q2 | 3034.00 USD | 129.46% |
| 2002 FY | 7239.00 USD | 0.0% |
| 2000 Q2 | 168.92 Thousand USD | -8.97% |
| 2000 Q1 | 185.56 Thousand USD | 96.29% |
| 1999 FY | 2.43 Million USD | -28.24% |
| 1999 Q4 | 94.53 Thousand USD | -86.95% |
| 1999 Q3 | 724.38 Thousand USD | 0.0% |
| 1998 FY | 3.38 Million USD | -26.51% |
| 1997 Q1 | 1.2 Million USD | 45.18% |
| 1997 FY | 4.61 Million USD | 14.51% |
| 1996 Q1 | 1.1 Million USD | 37.5% |
| 1996 Q2 | 1.2 Million USD | 9.09% |
| 1996 FY | 4.02 Million USD | 49.13% |
| 1996 Q3 | 900 Thousand USD | -25.0% |
| 1996 Q4 | 826.56 Thousand USD | -8.16% |
| 1995 Q2 | 600 Thousand USD | 0.0% |
| 1995 Q4 | 800 Thousand USD | 14.29% |
| 1995 Q3 | 700 Thousand USD | 16.67% |
| 1995 Q1 | 600 Thousand USD | 0.0% |
| 1995 FY | 2.7 Million USD | 28.57% |
| 1994 Q2 | 900 Thousand USD | 0.0% |
| 1994 Q3 | 500 Thousand USD | -44.44% |
| 1994 Q4 | 600 Thousand USD | 20.0% |
| 1994 FY | 2.1 Million USD | 0.0% |
| 1994 Q1 | 900 Thousand USD | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | - USD | -Infinity% |
| Arch Therapeutics, Inc. | -2439.00 USD | 227.183% |
| Evofem Biosciences, Inc. | 11.7 Million USD | 99.974% |
| Nascent Biotech, Inc. | -319.5 Thousand USD | 100.971% |
| Rebus Holdings, Inc. | - USD | -Infinity% |
| Santhera Pharmaceuticals Holding AG | 119.1 Million USD | 99.997% |
| Qrons Inc. | - USD | -Infinity% |
| Adynxx, Inc. | - USD | -Infinity% |
| Neon Bloom, Inc. | - USD | -Infinity% |
| Northwest Biotherapeutics, Inc. | -25.79 Million USD | 100.012% |
| ProtoKinetix, Incorporated | -48.25 Thousand USD | 106.428% |
| Skye Bioscience, Inc. | -124.25 Thousand USD | 102.497% |
| Eiger BioPharmaceuticals, Inc. | 14.99 Million USD | 99.979% |
| Institute of Biomedical Research Corp. | - USD | -Infinity% |
| SQZ Biotechnologies Company | 9.79 Million USD | 99.968% |
| Intellipharmaceutics International Inc. | 65.72 Thousand USD | 95.281% |
| Propanc Biopharma, Inc. | -34.15 Thousand USD | 109.083% |
| Mesoblast Limited | -35.16 Million USD | 100.009% |
| Marizyme, Inc. | 457.7 Thousand USD | 99.322% |
| Genus plc | 178.7 Million USD | 99.998% |
| VioQuest Pharmaceuticals, Inc. | - USD | -Infinity% |
| Pharming Group N.V. | 220.1 Million USD | 99.999% |
| Therapeutic Solutions International, Inc. | 62.22 Thousand USD | 95.015% |
| CNBX Pharmaceuticals Inc. | 410.16 Thousand USD | 99.244% |
| Nymox Pharmaceutical Corporation | -11 Thousand USD | 128.2% |
| ContraFect Corporation | -154 Thousand USD | 102.014% |
| PsyBio Therapeutics Corp. | -50 Thousand USD | 106.204% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 76.76 Thousand USD | 95.959% |
| IMV Inc. | -962.29 Thousand USD | 100.322% |
| AXIM Biotechnologies, Inc. | -387.5 Thousand USD | 100.801% |
| MultiCell Technologies, Inc. | 49.32 USD | -6189.538% |
| ONE Bio Corp. | 20.12 Million USD | 99.985% |
| Accustem Sciences Inc. | - USD | -Infinity% |
| RVL Pharmaceuticals plc | 40.26 Million USD | 99.992% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 48.9 Thousand USD | 93.656% |
| Q BioMed Inc. | -8988.00 USD | 134.513% |
| Emmaus Life Sciences, Inc. | 28.25 Million USD | 99.989% |
| Mosaic ImmunoEngineering Inc. | - USD | -Infinity% |
| Biomind Labs Inc. | -15.42 Thousand USD | 120.112% |
| American Oriental Bioengineering, Inc. | 44.35 Million USD | 99.993% |
| Provectus Biopharmaceuticals, Inc. | -1.14 Million USD | 100.272% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 70 Thousand USD | 95.569% |
| GlobeStar Therapeutics Corporation | - USD | -Infinity% |
| THC Farmaceuticals, Inc. | -4952.00 USD | 162.641% |
| Acro Biomedical Co., Ltd. | 140.5 Thousand USD | 97.792% |
| Curative Biotechnology, Inc. | -97.51 Thousand USD | 103.181% |
| GB Sciences, Inc. | -624.00 USD | 597.115% |
| Alpha Cognition Inc. | -86.02 Thousand USD | 103.606% |
| HST Global, Inc. | - USD | -Infinity% |
| CSL Limited | 7.56 Billion USD | 100.0% |
| Wesana Health Holdings Inc. | - USD | -Infinity% |
| Halberd Corporation | -208.00 USD | 1591.346% |
| Enzolytics Inc. | 30.7 Thousand USD | 89.898% |
| Agentix Corp. | - USD | -Infinity% |
| Resverlogix Corp. | - USD | -Infinity% |
| Nuo Therapeutics, Inc. | 482.43 Thousand USD | 99.357% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 1.1 Billion USD | 100.0% |
| Enzon Pharmaceuticals, Inc. | - USD | -Infinity% |
| Endonovo Therapeutics, Inc. | -514.51 Thousand USD | 100.603% |
| RespireRx Pharmaceuticals Inc. | - USD | -Infinity% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | - USD | -Infinity% |
| AVAX Technologies, Inc. | 617.38 Thousand USD | 99.498% |
| Zenith Capital Corp. | - USD | -Infinity% |
| Genscript Biotech Corporation | 409.55 Million USD | 99.999% |
| Ember Therapeutics, Inc. | - USD | -Infinity% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | -8856.00 USD | 135.027% |
| WPD Pharmaceuticals Inc. | - USD | -Infinity% |
| Cotinga Pharmaceuticals Inc. | -83.84 Thousand USD | 103.7% |
| Kadimastem Ltd | -630.13 Thousand USD | 100.492% |
| Helix BioMedix, Inc. | 987.98 Thousand USD | 99.686% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 9.61 Million USD | 99.968% |
| BioStem Technologies, Inc. | 15.42 Million USD | 99.98% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | - USD | -Infinity% |
| LadRx Corporation | -11.83 Thousand USD | 126.21% |
| Cell Source, Inc. | - USD | -Infinity% |
| Regen BioPharma, Inc. | 176.56 Thousand USD | 98.243% |
| Regen BioPharma, Inc. | 176.56 Thousand USD | 98.243% |
| NovAccess Global Inc. | - USD | -Infinity% |
| Affymax, Inc. | 1.35 Million USD | 99.771% |
| Itoco Inc. | - USD | -Infinity% |
| Rasna Therapeutics, Inc. | - USD | -Infinity% |
| Pathfinder Cell Therapy, Inc. | - USD | -Infinity% |
| Mobile Lads Corp. | - USD | -Infinity% |
| CytoDyn Inc. | -29 Thousand USD | 110.697% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | - USD | -Infinity% |
| NanoSphere Health Sciences Inc. | - USD | -Infinity% |
| Alseres Pharmaceuticals, Inc. | 450.04 Thousand USD | 99.311% |
| SYBLEU INC | 11.69 Thousand USD | 73.478% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | - USD | -Infinity% |
| International Stem Cell Corporation | 4.6 Million USD | 99.933% |
| Bioxytran, Inc. | -8285.00 USD | 137.441% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | - USD | -Infinity% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | - USD | -Infinity% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | - USD | -Infinity% |
| Adhera Therapeutics, Inc. | - USD | -Infinity% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | - USD | -Infinity% |
| Innovation Pharmaceuticals Inc. | -373 Thousand USD | 100.832% |
| Neutra Corp. | 14.33 Thousand USD | 78.361% |
| Windtree Therapeutics, Inc. | -82 Thousand USD | 103.783% |
| PureTech Health plc | -1.6 Million USD | 100.194% |
| Coeptis Therapeutics, Inc. | -1 Million USD | 100.31% |
| IXICO plc | 3.27 Million USD | 99.905% |
| IntelGenx Technologies Corp. | -694 Thousand USD | 100.447% |
| Gelesis Holdings, Inc. | -1.79 Million USD | 100.173% |
| CSL Limited | 7.7 Billion USD | 100.0% |
| Cellectis S.A. | 18 Thousand USD | 82.767% |